BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 32315395)

  • 21. MYH9-related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations.
    Pecci A; Klersy C; Gresele P; Lee KJ; De Rocco D; Bozzi V; Russo G; Heller PG; Loffredo G; Ballmaier M; Fabris F; Beggiato E; Kahr WH; Pujol-Moix N; Platokouki H; Van Geet C; Noris P; Yerram P; Hermans C; Gerber B; Economou M; De Groot M; Zieger B; De Candia E; Fraticelli V; Kersseboom R; Piccoli GB; Zimmermann S; Fierro T; Glembotsky AC; Vianello F; Zaninetti C; Nicchia E; Güthner C; Baronci C; Seri M; Knight PJ; Balduini CL; Savoia A
    Hum Mutat; 2014 Feb; 35(2):236-47. PubMed ID: 24186861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered cytoskeleton organization in platelets from patients with MYH9-related disease.
    Canobbio I; Noris P; Pecci A; Balduini A; Balduini CL; Torti M
    J Thromb Haemost; 2005 May; 3(5):1026-35. PubMed ID: 15869600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion.
    Léon C; Eckly A; Hechler B; Aleil B; Freund M; Ravanat C; Jourdain M; Nonne C; Weber J; Tiedt R; Gratacap MP; Severin S; Cazenave JP; Lanza F; Skoda R; Gachet C
    Blood; 2007 Nov; 110(9):3183-91. PubMed ID: 17664350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A De Novo Mutation in MYH9 in a Child With Severe and Prolonged Macrothrombocytopenia.
    Li K; Jin R; Xu W; Shen Y; Lu K; Wu X
    J Pediatr Hematol Oncol; 2021 Jan; 43(1):e7-e10. PubMed ID: 32520844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease.
    Pecci A; Panza E; Pujol-Moix N; Klersy C; Di Bari F; Bozzi V; Gresele P; Lethagen S; Fabris F; Dufour C; Granata A; Doubek M; Pecoraro C; Koivisto PA; Heller PG; Iolascon A; Alvisi P; Schwabe D; De Candia E; Rocca B; Russo U; Ramenghi U; Noris P; Seri M; Balduini CL; Savoia A
    Hum Mutat; 2008 Mar; 29(3):409-17. PubMed ID: 18059020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway.
    Chen Z; Naveiras O; Balduini A; Mammoto A; Conti MA; Adelstein RS; Ingber D; Daley GQ; Shivdasani RA
    Blood; 2007 Jul; 110(1):171-9. PubMed ID: 17392504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-muscle myosin heavy chain IIA and IIB interact and co-localize in living cells: relevance for MYH9-related disease.
    Marini M; Bruschi M; Pecci A; Romagnoli R; Musante L; Candiano G; Ghiggeri GM; Balduini C; Seri M; Ravazzolo R
    Int J Mol Med; 2006 May; 17(5):729-36. PubMed ID: 16596254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MYH9-Related Thrombocytopenia: Four Novel Variants Affecting the Tail Domain of the Non-Muscle Myosin Heavy Chain IIA Associated with a Mild Clinical Evolution of the Disorder.
    Zaninetti C; De Rocco D; Giangregorio T; Bozzi V; Demeter J; Leoni P; Noris P; Ryhänen S; Barozzi S; Pecci A; Savoia A
    Hamostaseologie; 2019 Feb; 39(1):87-94. PubMed ID: 29996171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes.
    Heath KE; Campos-Barros A; Toren A; Rozenfeld-Granot G; Carlsson LE; Savige J; Denison JC; Gregory MC; White JG; Barker DF; Greinacher A; Epstein CJ; Glucksman MJ; Martignetti JA
    Am J Hum Genet; 2001 Nov; 69(5):1033-45. PubMed ID: 11590545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carboxyl-terminal-dependent recruitment of nonmuscle myosin II to megakaryocyte contractile ring during polyploidization.
    Badirou I; Pan J; Legrand C; Wang A; Lordier L; Boukour S; Roy A; Vainchenker W; Chang Y
    Blood; 2014 Oct; 124(16):2564-8. PubMed ID: 25185263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of nonmuscle myosin II isoforms determines localization at the cleavage furrow of megakaryocytes.
    Roy A; Lordier L; Mazzi S; Chang Y; Lapierre V; Larghero J; Debili N; Raslova H; Vainchenker W
    Blood; 2016 Dec; 128(26):3137-3145. PubMed ID: 27737892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful renal transplantation in MYH9-related disorder with severe macrothrombocytopenia: first report in Korea.
    Min SY; Ahn HJ; Park WS; Kim JW
    Transplant Proc; 2014; 46(2):654-6. PubMed ID: 24656038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. R705H mutation of MYH9 is associated with MYH9-related disease and not only with non-syndromic deafness DFNA17.
    Verver E; Pecci A; De Rocco D; Ryhänen S; Barozzi S; Kunst H; Topsakal V; Savoia A
    Clin Genet; 2015 Jul; 88(1):85-9. PubMed ID: 24890873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cloning of the murine non-muscle myosin heavy chain IIA gene ortholog of human MYH9 responsible for May-Hegglin, Sebastian, Fechtner, and Epstein syndromes.
    D'Apolito M; Guarnieri V; Boncristiano M; Zelante L; Savoia A
    Gene; 2002 Mar; 286(2):215-22. PubMed ID: 11943476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ADAP deficiency impairs megakaryocyte polarization with ectopic proplatelet release and causes microthrombocytopenia.
    Spindler M; van Eeuwijk JMM; Schurr Y; Nurden P; Nieswandt B; Stegner D; Reinhold A; Bender M
    Blood; 2018 Aug; 132(6):635-646. PubMed ID: 29950291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Autosomal dominant macrothrombocytopenia with leukocyte inclusion bodies and MYH9 disorders].
    Kunishima S
    Rinsho Byori; 2009 Apr; 57(4):365-70. PubMed ID: 19489439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression.
    Bluteau D; Glembotsky AC; Raimbault A; Balayn N; Gilles L; Rameau P; Nurden P; Alessi MC; Debili N; Vainchenker W; Heller PG; Favier R; Raslova H
    Blood; 2012 Sep; 120(13):2708-18. PubMed ID: 22898599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical, pathological, and genetic analysis of ten patients with MYH9-related disease.
    Sun XH; Wang ZY; Yang HY; Cao LJ; Su J; Yu ZQ; Bai X; Ruan CG
    Acta Haematol; 2013; 129(2):106-13. PubMed ID: 23207509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Avatrombopag improves thrombocytopenia in MYH9-related disorder following eltrombopag treatment failure.
    Arif AR; Zhao M; Chen W; Xue M; Luo S; Wang Y
    Platelets; 2022 Nov; 33(8):1307-1311. PubMed ID: 35791514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role for formin-like 1-dependent acto-myosin assembly in lipid droplet dynamics and lipid storage.
    Pfisterer SG; Gateva G; Horvath P; Pirhonen J; Salo VT; Karhinen L; Varjosalo M; Ryhänen SJ; Lappalainen P; Ikonen E
    Nat Commun; 2017 Mar; 8():14858. PubMed ID: 28361956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.